
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences Inc. demonstrates a robust outlook due to the increasing probability of success (PoS) for its lead program, darovasertib, which is showing promising anti-tumor responses in early clinical studies. The synergistic effect observed when combined with crizotinib suggests enhanced efficacy and safety, bolstering expectations for robust performance in ongoing Phase 3 trials which may yield favorable results. Furthermore, IDEAYA's strategic focus on high-value oncology targets, alongside an anticipated peak revenue potential exceeding $3 billion, reinforces the positive growth trajectory for the company's stock.
Bears say
IDEAYA Biosciences Inc. faces a negative outlook primarily due to the unpredictability surrounding its future revenues and expenses, compounded by its current non-revenue-generating status. Key risks include potential negative trial outcomes for its product candidates, particularly IDE397 and IDE849, which could limit market potential and weaken investor confidence in the pipeline. Additionally, the company’s reliance on a single product, darovasertib (daro), exposes it to significant concentration risks, as any setbacks in clinical or commercial execution could adversely affect overall performance.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares